Has Tammi Labarre, NP received payments from drug or device companies?

Yes. Drug and device makers reported $2,577 in general payments to Tammi Labarre, NP across 138 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tammi Labarre, NP did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tammi Labarre, NP come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tammi Labarre, NP

Family · Slidell, LANPI 1992990626

Payments from drug & device makers

$2,577in general payments, 2019–2025

Across 138 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$707
Supernus Pharmaceuticals, Inc.$347
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$200
Biohaven Pharmaceuticals, Inc.$147
Noven Therapeutics, LLC$130
Antares Pharma, Inc.$116
plus $932 from 20 others

What the payments were for

Food & beverage$2,572100%
Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	30	$707
Supernus Pharmaceuticals, Inc.	27	$347
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	11	$200
Biohaven Pharmaceuticals, Inc.	2	$147
Noven Therapeutics, LLC	7	$130
Antares Pharma, Inc.	6	$116
Tris Pharma Inc	7	$116
Lilly USA, LLC	7	$108
Tolmar, Inc.	6	$107
Axsome Therapeutics, Inc.	5	$92
Takeda Pharmaceuticals U.S.A., Inc.	5	$87
Idorsia Pharmaceuticals US Inc	4	$61
Abbott	3	$54
Novo Nordisk	3	$44
Clarus Therapeutics Inc.	2	$39
Azurity Pharmaceuticals, Inc.	2	$35
Galderma Laboratories, L.p.	2	$31
Halozyme Inc	1	$24
Corium, LLC	1	$20
Otsuka America Pharmaceutical, Inc.	1	$18
Biohaven Pharmaceutical Holding Company Ltd.	1	$18
IBSA Pharma Inc.	1	$18
Currax Pharmaceuticals LLC	1	$17
Eisai Inc.	1	$15
Almatica Pharma LLC	1	$15
Dexcom, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VRAYLAR$125
NURTEC ODT$125

How this compares

$2,577 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana →

Medicare billing

Part B allowed, 2024

$9,920

Medicare patients

Services billed

157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MounjaroTirzepatide	38	$46,609
VraylarCariprazine Hcl	24	$35,103
EliquisApixaban	24	$16,358
LinzessLinaclotide	17	$12,660
JanuviaSitagliptin Phosphate	16	$10,375
BelsomraSuvorexant	20	$8,945
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine	31	$1,786
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	13	$1,182
Omega-3 Acid Ethyl Esters	12	$1,095
Rosuvastatin Calcium	64	$866
FenofibrateFenofibrate Nanocrystallized	34	$722
ProgesteroneProgesterone, Micronized	27	$678
Albuterol Sulfate HfaAlbuterol Sulfate	26	$650
Ezetimibe	48	$581
Gabapentin	48	$578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieVraylar, Linzess	$707	$47,76441 claims
Lilly USA, LLCMounjaro	$108	$46,60938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.